JP2016511753A5 - - Google Patents

Download PDF

Info

Publication number
JP2016511753A5
JP2016511753A5 JP2015555661A JP2015555661A JP2016511753A5 JP 2016511753 A5 JP2016511753 A5 JP 2016511753A5 JP 2015555661 A JP2015555661 A JP 2015555661A JP 2015555661 A JP2015555661 A JP 2015555661A JP 2016511753 A5 JP2016511753 A5 JP 2016511753A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
hepe
present
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015555661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511753A (ja
JP6363104B2 (ja
Filing date
Publication date
Priority claimed from GBGB1301626.6A external-priority patent/GB201301626D0/en
Application filed filed Critical
Publication of JP2016511753A publication Critical patent/JP2016511753A/ja
Publication of JP2016511753A5 publication Critical patent/JP2016511753A5/ja
Application granted granted Critical
Publication of JP6363104B2 publication Critical patent/JP6363104B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015555661A 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法 Expired - Fee Related JP6363104B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1301626.6 2013-01-30
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
PCT/EP2014/051455 WO2014118097A1 (en) 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018121494A Division JP2018172409A (ja) 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法

Publications (3)

Publication Number Publication Date
JP2016511753A JP2016511753A (ja) 2016-04-21
JP2016511753A5 true JP2016511753A5 (cg-RX-API-DMAC10.html) 2017-02-23
JP6363104B2 JP6363104B2 (ja) 2018-07-25

Family

ID=47891001

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555661A Expired - Fee Related JP6363104B2 (ja) 2013-01-30 2014-01-24 15−ohepaを含む組成物および同組成物を使用する方法
JP2018121494A Pending JP2018172409A (ja) 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018121494A Pending JP2018172409A (ja) 2013-01-30 2018-06-27 15−ohepaを含む組成物および同組成物を使用する方法

Country Status (27)

Country Link
US (6) US20150224076A1 (cg-RX-API-DMAC10.html)
EP (2) EP2762143B1 (cg-RX-API-DMAC10.html)
JP (2) JP6363104B2 (cg-RX-API-DMAC10.html)
KR (6) KR20230047201A (cg-RX-API-DMAC10.html)
CN (2) CN111214464A (cg-RX-API-DMAC10.html)
AU (2) AU2014211628B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015018270A2 (cg-RX-API-DMAC10.html)
CA (1) CA2897343C (cg-RX-API-DMAC10.html)
CY (1) CY1117209T1 (cg-RX-API-DMAC10.html)
DK (1) DK2762143T3 (cg-RX-API-DMAC10.html)
ES (2) ES2564025T3 (cg-RX-API-DMAC10.html)
GB (1) GB201301626D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20160203T1 (cg-RX-API-DMAC10.html)
HU (1) HUE026901T2 (cg-RX-API-DMAC10.html)
IL (3) IL239893A (cg-RX-API-DMAC10.html)
MX (2) MX364646B (cg-RX-API-DMAC10.html)
NZ (1) NZ709803A (cg-RX-API-DMAC10.html)
PH (1) PH12015501582B1 (cg-RX-API-DMAC10.html)
PL (1) PL2762143T3 (cg-RX-API-DMAC10.html)
PT (1) PT2762143E (cg-RX-API-DMAC10.html)
RS (1) RS54584B1 (cg-RX-API-DMAC10.html)
RU (2) RU2671208C2 (cg-RX-API-DMAC10.html)
SG (2) SG10201806854XA (cg-RX-API-DMAC10.html)
SI (1) SI2762143T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201600069B (cg-RX-API-DMAC10.html)
WO (1) WO2014118097A1 (cg-RX-API-DMAC10.html)
ZA (2) ZA201505018B (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105899485B (zh) 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
US20150196521A1 (en) * 2014-01-10 2015-07-16 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN113893240A (zh) * 2015-01-16 2022-01-07 艾菲穆恩有限公司 包含15-hepe的组合物和其使用方法
KR20240033300A (ko) 2015-04-28 2024-03-12 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
HK1250345A1 (zh) * 2015-05-13 2018-12-14 Afimmune Limited 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
MX379262B (es) * 2015-12-18 2025-03-10 Afimmune Ltd Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
CA3084728A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU673700B2 (en) 1993-01-27 1996-11-21 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール.ピー.シェーラー コーポレイション 香料を小分けして提供する方法および組成物
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
CN100357244C (zh) * 2000-02-16 2007-12-26 布里格姆及妇女医院股份有限公司 阿司匹林触发的脂质介体
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
ES2238568T3 (es) 2001-05-30 2005-09-01 Laxdale Limited Uso del coenzima q (ubiquinona) y acido eicosapentaenoico (epa) para el tratamiento del linfoma no hodgkin y trastornos psiquiatricos o neurologicos.
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060009522A1 (en) 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
EP1973536A2 (en) * 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
CA2662987A1 (en) 2006-08-08 2008-02-21 Tethys Bioscience, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
ES2555782T3 (es) * 2007-03-30 2016-01-08 Kowa Company, Ltd. Fármaco para prevenir y/o tratar hígado graso o esteatosis hepática no alcohólica
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20110105510A1 (en) * 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
US8853437B2 (en) * 2009-02-20 2014-10-07 The University Of Tokyo Anti-inflammatory compounds
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
EP2607358A4 (en) * 2010-08-19 2014-01-29 Univ Tokyo NEW OMEGA-3 FATTY ACIDS RECOVERY-RESISTANT METABOLITE
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
WO2012135032A2 (en) 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
SG11201401629XA (en) 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
BR112014013098A2 (pt) 2011-11-29 2017-06-13 Dignity Sciences Ltd composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
KR102153245B1 (ko) 2012-01-06 2020-09-08 옴테라 파마슈티칼스, 인크. 유리 산 형태의 오메가-3 다중불포화 지방산의 dpa-농축 조성물
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
AU2013259503B2 (en) * 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN112245420A (zh) * 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
MX379262B (es) 2015-12-18 2025-03-10 Afimmune Ltd Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.

Similar Documents

Publication Publication Date Title
JP2016511753A5 (cg-RX-API-DMAC10.html)
JP2017513836A5 (cg-RX-API-DMAC10.html)
HRP20160203T1 (hr) Pripravci koji sadrže 15-hepe i postupci njihove upotrebe
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2015143248A5 (cg-RX-API-DMAC10.html)
RU2018133298A (ru) Способы применения агонистов fxr
CO7240414A2 (es) Preparación y usos de ácido obeticólico
AR122580A2 (es) Forma de dosificación de doxilamina y piridoxina y/o sus metabolitos o sales
JP2014129360A5 (cg-RX-API-DMAC10.html)
HRP20192299T1 (hr) Liječenje nafld i nash
JP2017505285A5 (cg-RX-API-DMAC10.html)
EA201790124A1 (ru) Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения
JP2014218522A5 (cg-RX-API-DMAC10.html)
JP2009530398A5 (cg-RX-API-DMAC10.html)
JP2016510326A5 (cg-RX-API-DMAC10.html)
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CN103717571B8 (zh) 9‑氨基甲基取代的四环素类化合物
JP2020500875A5 (cg-RX-API-DMAC10.html)
JP2017505809A5 (cg-RX-API-DMAC10.html)
JP2015510916A5 (cg-RX-API-DMAC10.html)
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
RU2016145066A (ru) Композиция для предотвращения или лечения жировых болезней печени
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2018537513A5 (cg-RX-API-DMAC10.html)